Sugammadex Sodium|CAS 343306-79-6|DC Chemicals

Cas No.:	343306-79-6
Chemical Name:	Sugammadex Sodium
Synonyms:	6A,6B,6C,6D,6E,6F,6G,6H-Octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,6F,6G-octasulfanyl-gamma-cyclodextrin octasodium salt;ORG-25969;Bridion;Sugammadex;Sugammadex sodium;Org 25969;ERJ6X2MXV7;Sugammadex sodium [USAN:JAN];Bridion (TN);Sugammadex sodium (JAN/USAN);D05940;Octasodium 6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octakis-S-(2-carboxylatoethyl)-6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octathiocyclo-alpha-(1-4)-D-octaglucopyranoside;gamma-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-oct
SMILES:	S(C([H])([H])C([H])([H])C(=O)[O-])C([H])([H])[C@]1([H])[C@]2([H])[C@@]([H])([C@]([H])([C@]([H])(O1)O[C@]1([H])[C@@]([H])(C([H])([H])SC([H])([H])C([H])([H])C(=O)[O-])O[C@@]([H])([C@@]([H])([C@@]1([H])O[H])O[H])O[C@]1([H])[C@@]([H])(C([H])([H])SC([H])([H])C([H])([H])C(=O)[O-])O[C@@]([H])([C@@]([H])([C@@]1([H])O[H])O[H])O[C@]1([H])[C@@]([H])(C([H])([H])SC([H])([H])C([H])([H])C(=O)[O-])O[C@@]([H])([C@@]([H])([C@@]1([H])O[H])O[H])O[C@]1([H])[C@@]([H])(C([H])([H])SC([H])([H])C([H])([H])C(=O)[O-])O[C@@]([H])([C@@]([H])([C@@]1([H])O[H])O[H])O[C@]1([H])[C@@]([H])(C([H])([H])SC([H])([H])C([H])([H])C(=O)[O-])O[C@@]([H])([C@@]([H])([C@@]1([H])O[H])O[H])O[C@]1([H])[C@@]([H])(C([H])([H])SC([H])([H])C([H])([H])C(=O)[O-])O[C@@]([H])([C@@]([H])([C@@]1([H])O[H])O[H])O[C@]1([H])[C@@]([H])(C([H])([H])SC([H])([H])C([H])([H])C(=O)[O-])O[C@@]([H])([C@@]([H])([C@@]1([H])O[H])O[H])O2)O[H])O[H].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Formula:	C₇₂H₁₀₄Na₈O₄₈S₈
M.Wt:	2178.0055
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Sugammadex sodium is a synthetic γ-cyclodextrin derivative, and acts as a new reversal agent for neuromuscular block.
In Vivo:	Injection of sugammadex has no significant effects on blood pressure or heart rate. After injection of the high rocuronium dose, the 90% recovery of the train-of-four ratio takes 28 min (SD 7 min) after saline, 26 min (SD 9.5 min) after 1 mg/kg sugammadex, and 8 min (SD 3.6 min) after 2.5 mg/kg sugammadex[1]. Sugammadex causes a rapid and complete reversal of rocuronium-induced neuromuscular block. The recovery time to train of four ratio=0.9 after spontaneous recovery is 14.4 min (SD=3.4 min; n=14). This is reduced significantly to 3.7 min (SD=3.3 min; n=4) with sugammadex 0.5 mg/kg and to 1.9 min (SD=1.0 min; n=4) with sugammadex 1.0 mg/kg[2]. The estimated half-life of sugammadex in Rhesus monkey is 30 (SEM=4.9) min[3].
Animal Administration:	Female rhesus monkeys with a body weight of 5.2-7.1 kg are sedated with 10 mg/kg ketamine intramuscularly. Two intravenous lines are placed: one for anesthetic administration, including rocuronium, the other for test drug administration. This is followed by intravenous injection of 25 mg/kg pentobarbitone sodium and a subsequent continuous infusion of 5-10 mg/kg/h. The monkeys are intubated endotracheally, and the lungs are ventilated with a mixture of oxygen and nitrous oxide (volume ratio of 2:3). Four animals are each studied on three different occasions. The occasions differed by the administration of either saline or a low (1.0 mg/kg) or high (2.5 mg/kg) dose of sugammadex. Between the experiments, the monkeys recover for at least 6 weeks. Heart rate and oxygen saturation are determined at the ear with a pulse oximeter. Blood pressure is determined with a cuff placed around the tail. Body temperature is measured by a rectal probe and kept at 37°C-38°C.
References:	[1]. de Boer HD, et al. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology. 2006 Apr;104(4):718-23. [2]. de Boer HD, et al. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth. 2006 Apr;96(4):473-9. Epub 2006 Feb 7. [3]. de Boer HD, et al. Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. Br J Anaesth. 2006 Nov;97(5):681-6. Epub 2006 Oct 3.

Cat. No.	Product name	Field of application
DC31079	Abarelix	Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79856	EVT0185	EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
DC79609	NCGC00685960	NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC79112	Simepdekinra	Simepdekinra (Compound 221) is a IL-17A modulator with IC50s ≤10  nM and 10-100 nM for IL-17A/A HEK-Blue and IL-17A/F HEK-Blue cells. Simepdekinra can be used for inflammatory diseases such as psoriasis, ankylosing spondylitis and psoriatic arthritis research.
DC78751	RSL3-NH2	RSL3-NH2 is a GPX4 inhibitor and Ferroptosis inducer. RSL3-NH2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
DC77831	Vicadrostat	Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813	Zeltociclib	Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77784	UNC10013	UNC10013 is a SETDB1 allosteric modulator that forms a covalent bond with Cys385 in the 3TD domain, exhibiting negative allosteric regulatory activity. It has a kinact/KI value of 1.0 × 106 M-1*s-1. UNC10013 effectively disrupts SETDB1-mediated Akt methylation and holds potential value for research in cancer and neurodegenerative diseases.
DC77740	T0080	T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE−/− mice.